Hepatitis Therapeutics Market Foreseen to Draw a Promising Growth of CAGR by 2025 | Leading Company’s - J&J, Gilead, Bristol-Myers Squibb, Merck, AbbVie

Overview of Global Hepatitis Therapeutics Market:

This report provides in-depth study of “Global Hepatitis Therapeutics Market 2020” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Hepatitis Therapeutics Market report also provides an in-depth survey of key players in the market organization.

Major key factors driving the growth of the Global Hepatitis Therapeutics Market are increasing number of hepatitis infected population, rise in the number of autoimmune disease, growing consumption of alcohol & drugs, and improving accessibility to hepatitis drugs and surge in healthcare expenditures across the globe. According to the WHO, around 1.75 million new HCV infections occur each year, and approximately 399,400 deaths were caused due to HCV in 2015. Increase in the usage of unsterilized equipment and infected syringes, medication errors, and transfusion of infectious blood are leading to an increase in the incidence of viral diseases such as Hepatitis C. This, in turn, is likely to fuel demand for hepatitis therapeutics across the globe.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/273349 .

Firstly, the report provides a basic overview of the Market including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major Market players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2020-2025 market shares for each company.

Based on the regional analysis, North America accounted for a major share of the global market in 2017. Increasing incidence of and mortality caused due to hepatitis and increased spending on drugs for the treatment of hepatitis in the U.S. are likely to boost the Hepatitis Therapeutics Market in the region. Europe is anticipated to account for a significant share of the global market between 2018 and 2025. The market in APAC is likely to expand at a significant CAGR during the forecast period. Increasing prevalence of chronic hepatitis C in developing countries such as China and India and favorable government initiatives for creating awareness about hepatitis are projected to propel the market in the region in the next few years.

In the end, the report makes some important proposals for a new project of Hepatitis Therapeutics Market before evaluating its feasibility. Overall, the report provides an in-depth insight of 2013-2025 global Hepatitis Therapeutics market covering all important parameters.

Global Key Vendors:

1 Gilead

2 Johnson & Johnson

3 Bristol-Myers Squibb Company

4 Merck & Co.Inc.

5 AbbVie and More………………….

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Hepatitis Therapeutics Market Report 2020” @ https://www.businessindustryreports.com/buy-now/273349/single .

Product Type Segmentation

1 Hepatitis Vaccine

2 Anti-Viral Drugs

Industry Segmentation

1 Hepatitis A

2 Hepatitis B

3 Hepatitis C

4 Alcoholic Hepatitis

International Medical Industry News:

Merck (July 06, 2020) - Merck Announces VAR2 Pharmaceuticals as Winner of its Advance Biotech Grant - Merck, a leading science and technology company, today announced that VAR2 Pharmaceuticals has been selected as the European winner of its 2020 Advance Biotech Grant Program. Copenhagen, Denmark-based biotechnology company VAR2 Pharmaceuticals was chosen for its development of a promising novel cancer treatment that has the potential to treat multiple types of human solid tumors.

“Emerging biotech companies play a significant role in the pharma value chain, typically developing therapies for rare and orphan diseases and often need support in bringing these important drugs to market,” said Udit Batra, member of the Merck Executive Board and CEO, Life Science. “VAR2 Pharmaceuticals’ use of a malaria protein to treat cancer is promising, and we are proud to support them.”

VAR2 Pharmaceuticals is in pre-clinical development of a drug conjugate that uses a recombinant malaria protein, rVAR2, to target and combat cancer cells. The rVAR2 protein has been tested on different cancer cell lines and has, in such tests, bound to the vast majority, including melanoma, lymphoma, breast, prostate and ovarian cancer, and Hodgkin's lymphoma. Although today’s focus on Covid-19 vaccines, treatments and diagnostics development is critical, patients around the world need drugs to treat diseases like cancer. With its potential ability to rapidly shrink tumors and target a broad range of cancer cell lines without knowingly disrupting healthy cells, rVAR2 shows promise to be a safe and effective therapy against a broad range of cancers that have virtually no treatment options available.

As part of the grant award, VAR2 Pharmaceuticals will receive in-kind Merck products and consultation support to advance its harvest, downstream, and formulations process development challenges in the production of its drug-conjugated malaria protein.

“We are honored to have been selected as the winner of Merck’s Advance Biotech Grant,” said Ali Salanti, founder and CEO of VAR2 Pharmaceuticals. “The products, process development support and expertise belonging to the Life Science business of Merck in developing biopharmaceutical manufacturing processes will be instrumental in moving this project forward to GMP to enable clinical trials, and we look forward to the collaboration.”

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/273349 .

Major Points in Table of Contents:

Global Hepatitis Therapeutics Market Report 2020

1 Hepatitis Therapeutics Product Definition

2 Global Hepatitis Therapeutics Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Hepatitis Therapeutics Shipments

2.2 Global Manufacturer Hepatitis Therapeutics Business Revenue

2.3 Global Hepatitis Therapeutics Market Overview

2.4 COVID-19 Impact on Hepatitis Therapeutics Industry

3 Manufacturer Hepatitis Therapeutics Business Introduction

3.1 Gilead Hepatitis Therapeutics Business Introduction

3.2 Johnson & Johnson Hepatitis Therapeutics Business Introduction

3.3 Bristol-Myers Squibb Company Hepatitis Therapeutics Business Introduction

3.4 Merck & Co.Inc. Hepatitis Therapeutics Business Introduction

3.5 AbbVie Inc. Hepatitis Therapeutics Business Introduction

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.